[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-malignancies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-malignancies":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,64,86,112,134,160,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644081","theranostic-pet-for-target-validation-and-tumor-detection-100644081",false,"NCT07664410","Theranostic PET for Target Validation and Tumor Detection","TheranosticPET","Inclusion Criteria:\n\n1. PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine\n2. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Patient cannot give consent for the study\n2. Patient cannot lie flat or tolerate PET imaging\n3. Unwillingness or inability to comply with study and follow-up procedures\n4. Condition of patient which is critical to participate in this study in the discretion of the investigators\n5. Pregnant, lactating, or breast-feeding women","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","12 Months","OBSERVATIONAL","Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department.\n\nThe aim of this study is to collect data on the expression of target molecules\u002Freceptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET\u002FCT or PET\u002FMRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions.\n\nPrimary Endpoint:\n\nAssociation between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.",[25],"Solid Malignancies","RECRUITING","2026-06-17",{"date":29,"type":30},"2026-06-24","ACTUAL",{"date":32,"type":30},"2025-09-23",{"date":34,"type":20},"2035-09-23",{"name":36,"class":37},"University Hospital, Essen","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100579351","phase-1-a-phase-1-study-of-im-1021-in-participants-with-advanced-cancer-100579351","NCT06823167","A Phase 1 Study of IM-1021 in Participants With Advanced Cancer","A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies","Inclusion Criteria:\n\n1. Informed consent signed by the participant prior to conducting study-specific procedures\n2. ≥18 years of age\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n4. Histological or cytological diagnosis of:\n\n   Part A: advanced B-cell lymphomas or solid tumors, of the following subtypes:\n\n   B-cell Lymphomas:\n   * Mantle cell lymphoma (MCL)\n   * Diffuse large B-cell lymphoma (DLBCL) (including Richter's transformation)\n   * Follicular lymphoma\n   * Small lymphocytic lymphoma (SLL)\n\n   Solid Tumors:\n   * Pancreatic cancer\n   * Non-squamous non-small cell lung cancer (NSCLC)\n   * Malignant mesothelioma\n   * Epithelial ovarian cancer. Participants with fallopian tube and\u002For peritoneal malignancies are also eligible.\n   * Triple-negative breast cancer.\n   * Liposarcoma\n\n   Other, unlisted histologies, if approved by the Sponsor Medical Monitor\n\n   Part B Cohorts B1, B2, and B3:\n\n   Histological or cytological diagnosis of the cohort-specific disease indication. Indications may include those listed in Inclusion Criterion 4.a\n5. Participants must have adequate organ function.\n6. Participants must have a negative pregnancy test, be willing to practice highly effective methods of birth control, use condoms, and refrain from oocyte\u002Fsperm donation, as applicable, as detailed in the protocol.\n7. Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit. Participants with B-cell malignancies should have received at least two lines of therapy, including available therapies with established benefit. Participants with SLL should have received at least three prior lines of therapy.\n8. Participants must have measurable disease as per the relevant response assessment framework: Lugano Classification for lymphoma (except SLL) , per iwCLL criteria for SLL , and per RECIST v.1.1 for solid tumors.\n\nExclusion Criteria:\n\n1. Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.\n2. Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).\n3. History of an anaphylactic reaction to irinotecan or ≥ grade 3 GI toxicity to prior irinotecan.\n4. Life expectancy \\\u003C 12 weeks.\n5. Prior solid organ transplant.\n6. Participants with symptomatic ascites or pleural effusion. Participants who are clinically stable for at least 2 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis or catheter) are eligible.\n7. Participant has a known active central nervous system (CNS) primary tumor or metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no radiological evidence of new or enlarging brain metastases, and are off steroids or on a stable dose up to an equivalent of prednisone 10 mg\u002Fday for at least 15 days prior to first dose of study medication. Participants who have symptoms consistent with CNS metastasis must have a negative magnetic resonance imaging (MRI) or other clinically appropriate imaging study if the participant is not able to undergo contrast-enhanced MRI and approved by the Sponsor Medical Monitor during the screening period.\n8. Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 2 years. Exception: The time requirement does not apply to participants who underwent successful definitive resection of certain cancers.\n9. Participant has certain other significant medical conditions including cardiac, pulmonary, and infectious disease as detailed in the protocol.\n10. Participant is pregnant, breastfeeding, or expecting to conceive within the projected duration of the study.",{"count":47,"type":20},117,"INTERVENTIONAL",[50],"PHASE1","IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.",[25,53],"Hematologic Malignancies",{"date":55,"type":30},"2026-06-22",{"date":57,"type":30},"2025-02-26",{"date":59,"type":20},"2029-02",{"name":61,"class":62},"Immunome, Inc.","INDUSTRY",17,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":48,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100631829","early-phase-1-a-phase-1-study-of-177lu-im-3050-in-participants-with-advanced-cancer-100631829","NCT07505771","A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer","A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Malignancies","Inclusion Criteria:\n\n* ≥18 years of age\n* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2\n* Histological or cytological diagnosis of a solid tumor\n* Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit.\n* Participants must have measurable disease as per RECIST v.1.1 based on imaging performed during Screening.\n* During screening, participants must have positive FAP PET\u002FCT uptake as described in criteria for continuation of IM-3050 treatment.\n* Participants must have adequate organ function.\n\nExclusion Criteria:\n\n* Participant has received certain prior radiation therapy as detailed in the protocol\n* Participant has undergone major surgery within 4 weeks or minor surgery within 2 weeks of starting 177Lu-IM-3050 or has known active central nervous system (CNS) primary tumor or metastases and\u002For carcinomatous meningitis.\n* Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 3 years.\n\nException: The time requirement does not apply to participants who underwent successful definitive resection of certain cancers.\n\n* Recent or ongoing serious infection or other significant medical condition as detailed in the protocol.\n* Participant has received an investigational product or been treated with an investigational device within 30 days, or 5 half-lives prior to receiving the FAP PET\u002FCT imaging tracer or 177Lu-IM-3050.",{"count":72,"type":20},105,[74],"EARLY_PHASE1","IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.",[25],"2026-06-16",{"date":79,"type":30},"2026-06-18",{"date":81,"type":20},"2026-06",{"date":83,"type":20},"2034-12",{"name":61,"class":62},2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":48,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":38},"100634345","phase-1-controlled-cold-exposure-combined-with-pd-1pd-l1-immunotherapy-in-solid-tumors-nivalis-100634345","NCT07538479","Controlled Cold Exposure Combined With PD-1\u002FPD-L1 Immunotherapy in Solid Tumors (NIVALIS)","NIVALIS Trial: A Single-Center, Prospective, Single-Arm, Open-Label Phase I Exploratory Study Evaluating the Safety, Feasibility, and Preliminary Antitumor Activity of Controlled Cold Exposure Combined With PD-1\u002FPD-L1 Immunotherapy in Patients With Solid Tumors","NIVALIS","Inclusion Criteria:\n\n* 1\\. Age 18-75 years, regardless of sex. 2. Histologically or cytologically confirmed malignant solid tumor. 3. Evaluated by the treating physician or multidisciplinary team (MDT) as currently planned to receive standard PD-1\u002FPD-L1 inhibitor monotherapy or a standard combination regimen containing PD-1\u002FPD-L1 inhibitors.\n\n  4\\. Applicable settings include neoadjuvant, perioperative, or conversion therapy, as well as unresectable locally advanced, recurrent, or metastatic disease planned for systemic therapy.\n\n  5\\. At least one evaluable lesion; for patients assessed by RECIST 1.1, at least one measurable lesion is required. Patients planned for surgery may also be included if adequate preoperative imaging and postoperative pathological assessment are available, even if RECIST measurability is not fully met.\n\n  6\\. ECOG performance status 0-1; selected patients with ECOG 2 may be enrolled at the investigator's discretion if considered able to tolerate the study procedures.\n\n  7\\. Expected survival ≥3 months. 8. Adequate major organ function, including hematologic, hepatic, renal, and electrolyte parameters acceptable for clinical study participation.\n\n  9\\. Cardiopulmonary function at rest adequate to tolerate the study procedures, without obvious abnormalities indicating intolerance to cold exposure.\n\n  10\\. Toxicities from prior antitumor therapy must have recovered to ≤ Grade 1, except for alopecia or clinically insignificant abnormalities judged by the investigator; for patients previously treated with PD-1\u002FPD-L1 inhibitors, at least 4 weeks must have elapsed before enrollment, and prior related adverse events must have recovered or stabilized sufficiently for re-exposure.\n\n  11\\. No clear contraindication to cold exposure, and deemed able to tolerate cold exposure combined with immunotherapy by the investigator.\n\n  12\\. Negative pregnancy test for women of childbearing potential; participants of reproductive potential must agree to use effective contraception during the study and for at least 3 months after the last dose.\n\n  13\\. Able to understand the study objectives, procedures, and potential risks, and willing to provide written informed consent.\n\n  14\\. For participants planned for neoadjuvant, perioperative, or conversion therapy, the investigator must confirm that study procedures will not delay planned surgery or other critical treatments.\n\nExclusion Criteria:\n\n* 1\\. Participation in another interventional clinical study or receipt of another investigational treatment within 4 weeks before study treatment initiation.\n\n  2\\. Uncontrolled active infection, including but not limited to severe bacterial, viral, or fungal infection, or active tuberculosis.\n\n  3\\. HIV infection; chronic HBV or HCV infection with uncontrolled viral replication or unacceptable liver function.\n\n  4\\. Known severe hypersensitivity to the intended PD-1\u002FPD-L1 inhibitor or its excipients.\n\n  5\\. Active autoimmune disease or a requirement for long-term moderate- to high-dose immunosuppressive therapy; physiological replacement-dose steroids may be allowed at the investigator's discretion.\n\n  6\\. Prior severe or life-threatening immune-related adverse events during PD-1\u002FPD-L1 inhibitor therapy that have not resolved or are considered high-risk for re-exposure.\n\n  7\\. Significant cardiovascular disease, including but not limited to unstable angina, severe arrhythmia, NYHA class III-IV heart failure, LVEF \\\u003C50%, or myocardial infarction, stroke, or severe thrombotic events within 6 months.\n\n  8\\. Severe chronic respiratory disease, especially conditions likely to worsen under cold stimulation, such as severe COPD or severe asthma.\n\n  9\\. Clear contraindications to cold exposure, including prior severe cold-related injury, cold urticaria, cryoglobulinemia, active Raynaud's syndrome, or other diseases judged by the investigator to preclude tolerance to a cold environment.\n\n  10\\. Uncontrolled symptomatic central nervous system metastases. 11. Severe psychiatric illness, cognitive impairment, substance abuse, or alcohol dependence that would interfere with compliance.\n\n  12\\. Pregnancy or breastfeeding. 13. Uncontrolled diabetes, severe malnutrition, marked frailty, or any other condition judged to make the participant unable to tolerate cold exposure or study procedures.\n\n  14\\. Any situation in which study participation may significantly delay standard therapy, planned surgery, or other critical treatment timing.","75 Years",{"count":96,"type":20},24,[50],"This is a single-center, prospective, single-arm, open-label phase I exploratory study that plans to enroll 24 participants with solid malignancies. All participants will receive controlled cold exposure in addition to standard PD-1\u002FPD-L1 inhibitor monotherapy or PD-1\u002FPD-L1 inhibitor-based standard combination therapy. A 2-day cold acclimation phase will precede formal intervention, consisting of approximately 20°C exposure for 8 hours on Day -2 and approximately 18°C exposure for 10 hours on Day -1. The first combination cycle begins on Day 1 concurrently with PD-1\u002FPD-L1-based treatment, with exposure to an 18°C temperature-controlled hospital room for 12 hours per day for 7 consecutive days. If tolerated, cold exposure may be repeated in subsequent PD-1\u002FPD-L1 treatment cycles. The primary objective is to evaluate safety, tolerability, and feasibility. Secondary objectives are to explore preliminary antitumor activity and the effects on brown adipose tissue activation, peripheral immune profiling, circulating cytokines, metabolomics, gut microbiota, patient-reported outcomes, and tumor immune\u002Fmetabolic biomarkers when paired tumor tissue is available.",[100,25,101,102],"Solid Tumors","Cold Exposure","Immunotherapy","2026-05-24",{"date":105,"type":30},"2026-05-28",{"date":107,"type":30},"2026-04-20",{"date":109,"type":20},"2029-06-30",{"name":111,"class":37},"West China Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":119,"targetDuration":4,"studyType":48,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100571832","phase-1-a-phase-1-study-of-skb571-in-subjects-with-advanced-solid-tumors-100571832","NCT06725381","A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors","A Phase 1 Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SKB571 for Injection in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Subjects aged 18-75 years at the time of signing the informed consent form\n2. Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumors .\n3. Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.1.\n4. Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1.\n5. Subjects who are assessed by the investigator to have an expected survival of ≥ 3 months.\n6. Subjects who have adequate organ function.\n7. Subjects who have recovered from all toxicities due to prior therapy .\n8. Male and female subjects must agree to use highly effective contraception methods during the study treatment.\n9. Subjects who voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Subjects with known active or untreated central nervous system (CNS) metastases.\n2. Subjects with other malignant tumors within 3 years prior to the first dose.\n3. Subjects with history of major cardiovascular, cerebrovascular, or thromboembolic disease.\n4. Subjects with known active pulmonary tuberculosis.\n5. Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C.\n6. Subjects with major surgery within 28 days prior to the first dose.\n7. Subjects with known allergy or hypersensitivity to SKB571 or its excipients.\n8. Subjects with clinically severe lung injuries due to pulmonary complications.\n9. Subjects with a history of allogeneic tissue\u002Fsolid organ transplant.\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites effusion requiring repeated drainage.\n11. Subjects who have received live vaccines within 30 days prior to the first dose of study treatment, or who are scheduled to receive live vaccines during the study.\n12. Subjects who have received strong cytochrome P450 (CYP3A4) inhibitors or inducers, or BCRP inhibitors within 2 weeks prior to the first dose of study treatment or within 5 half-lives of known drug, whichever is longer.\n13. Subjects who have received chemotherapy, immunotherapy, or biological therapy within 4 weeks prior to the first dose of study treatment.\n14. Subjects with active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study treatment.\n15. Subjects with any disease requiring systemic treatment with corticosteroids (prednisone at doses \\> 10 mg\u002Fd or similar drugs with equivalent doses) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment.\n16. Subjects have received an investigational agent or has used an investigational device within 28 days prior to initial dose administration of SKB571.\n17. Subjects whose condition deteriorates rapidly before the first dose, such as a severe physical impariment or a change in ECOG score no longer meeting the inclusion criteria.\n18. Subjects with a known history of psychosis or drug abuse that will preclude the subject from completing the study.\n19. Any condition that, in the opinion of the investigator, will interfere with the assessment of study treatment or the safety of the subject or the interpretation of the study results.",{"count":120,"type":20},138,[50],"This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .",[25],"2026-05-05",{"date":126,"type":30},"2026-05-08",{"date":128,"type":30},"2024-12-17",{"date":130,"type":20},"2027-12",{"name":132,"class":62},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",15,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":48,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100562255","phase-1-a-modular-phase-12-study-with-ct7439-in-participants-with-solid-malignancies-100562255","NCT06600789","A Modular Phase 1\u002F2 Study With CT7439 in Participants With Solid Malignancies","A Modular, Multi-Part, Multi-Arm, Phase 1\u002F2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies","Core Inclusion Criteria:\n\n* Histopathologically or cytologically confirmed diagnosis of malignant disease evaluable by RECIST v1.1\n* Provision of signed written informed consent before any study-related activities, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures and willing to permit access to stored historical tumor tissue, prior tumor radiological assessments and tumor biomarker data.\n* ECOG performance status of ≤ 2 with no deterioration over the previous 2 weeks.\n* Ability to take oral medications and be willing to record daily adherence to the study drug.\n* Women either of non-childbearing potential, either confirmed to be post-menopausal or of childbearing potential willing to practice effective contraception for the duration of the study and for minimum 33 days after the last dose of CT7439.\n* Sexually active male patients must be willing to refrain from sperm donation from the time of signing informed consent and use condoms with all sexual partners for the duration of the study and for a minimum 93 days months after the last dose of CT7439.\n* Estimated life expectancy of at least 3 months, in the opinion of the investigator.\n\nCore Exclusion Criteria:\n\n* Prior therapy with a specific CDK12\u002F13 inhibitor, within any timeframe prior to the first dose of CT7439.\n* Participants with any other malignancy that have been active or treated within the past 3 years prior to enrolment, with the exception of cervical intraepithelial neoplasia and non-melanoma skin cancer.\n* Any unresolved toxicity (except alopecia) from prior therapy of ≥ 2 Common Terminology Criteria for Adverse Events (CTCAE) Grade.\n* Active or documented history of autoimmune disease.\n* Any current or prior central nervous system metastases\n* Active infection requiring systemic antibiotic, antifungal, or antiviral medication within 14 days prior to first dose of study drug.\n* Severe or uncontrolled medical condition or psychiatric condition.\n* Human immunodeficiency virus (HIV) infection, unless the study participant on anti-retroviral therapy for at least 4 weeks (28 days),and has not had an opportunistic infection within the past 12 months prior to enrollment.\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, unless participant with HBV patient is on a suppressive antiviral therapy, or participant with HCV has a viral load below the limit of quantification (LoQ).\n* Participant is breastfeeding or pregnant.\n* Receipt of cytotoxic and\u002For non- cytotoxic treatment for the malignancy within 28 days before the first dose of IMP.\n* Receipt of corticosteroids within 14 days before the first dose of IMP.\n* Receipt of any small molecule IMP within 28 days or 5 half-lives, whichever is longer, before the first dose of IMP.\n* Receipt of concomitant medication, herbal supplement, or food that is a moderate and\u002For strong inhibitor or inducer of CYP3A4,,strong inhibitor or inducer of CYP2D6 or P-gp or inhibitor of BCRP within 21 days before the first dose of IMP.\n* Inadequate hepatic, renal and bone marrow function, receipt of a blood transfusion (blood or blood products) within 14 days before the first dose of IMP.\n* Persistent (\\> 4 weeks) severe pancytopenia due to previous therapy rather than to disease (ANC \\< 0.5 × 109\u002FL or platelets \\< 50 x 109\u002FL).\n* History of cardiac dysfunction and\u002For presence of clinically significant cardiovascular disease\n* Has received a live virus vaccination within 28 days or less of planned treatment start.\n\nAdditional Module 1 inclusion criteria:\n\n1\\. Clinically confirmed locally advanced or metastatic solid malignancy for which there is no potentially curative treatment option.",{"count":142,"type":20},50,[50,144],"PHASE2","This modular, multi-part, multi-arm, Phase 1\u002F2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.",[25],[25,148,149],"Cancer Treatment","First In Human","2025-10-31",{"date":152,"type":30},"2025-11-03",{"date":154,"type":30},"2024-08-16",{"date":156,"type":20},"2026-05-22",{"name":158,"class":62},"Carrick Therapeutics Limited",6,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":167,"targetDuration":4,"studyType":48,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":38},"100587798","phase-1-safety-and-tolerability-of-cmab017-in-patients-with-advanced-solid-tumors-100587798","NCT06933069","Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors","A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Anti-tumor Activity of CMAB017 in Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n1. fully understand and agree to sign the Informed Consent Form (ICF);\n2. histologically or cytologically confirmed, inoperable, locally advanced, recurrent or metastatic malignant solid tumors, including but not limited to head and neck squamous carcinoma, RAS wild-type colorectal cancer, esophageal squamous carcinoma, etc., for which the patient has failed standard treatment, does not have standard treatment, or refuses standard treatment;\n3. age 18\\~75 years old, gender is not limited;\n4. Eastern Cooperative Oncology Group (ECOG) score ≤1;\n5. expected survival ≥ 3 months;\n6. presence of at least one evaluable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (bone-only metastases or central nervous system-only metastases will not be accepted as evaluable lesions); starting from 6 mg\u002Fkg Q3W, 4 mg\u002Fkg Q2W after the start of the dose group, presence of at least one measurable lesion; and dose groups, at least one measurable lesion is present (bone-only metastases or CNS-only metastases will not be accepted as measurable lesions);\n7. females of childbearing potential must be non-lactating and have a negative serum pregnancy test within 1 week prior to the first infusion and agree to use effective contraception from the time of signing the ICF until 6 months after the last infusion; male subjects must agree to use effective contraception from the time of signing the ICF until 6 months after the last infusion;\n8. Blood routine and liver and kidney functions during the screening period meet the following conditions:\n\n   * Blood routine: neutrophils ≥1.5×109\u002FL; platelets ≥75×109\u002FL; hemoglobin ≥90 g\u002FL;\n\n     * Liver function: alanine aminotransferase and aspartate aminotransferase ≤3×ULN (both should be ≤5×ULN for those with tumor liver metastasis); total bilirubin ≤1.5×ULN; ③ Coagulation function: activated partial thromboplastin time (APTT) ≤1.5×ULN; international normalized ratio (INR) ≤1.5×ULN (for patients not receiving anticoagulation therapy; APTT or INR of subjects receiving anticoagulation therapy should be within the expected therapeutic range of anticoagulant drugs); ④ Renal function: blood creatinine ≤ 1.5 x ULN; if creatinine \\> 1.5 x ULN, creatinine clearance (Ccr) \\> 50mL\u002Fmin is required (calculated according to the Cockcroft-Gault formula).\n\nExclusion Criteria:\n\n1. With known active CNS metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may be enrolled in the study provided that they have been clinically stable for at least 2 weeks, have no evidence of new or expanding brain metastases, and have discontinued steroids within 2 weeks prior to the infusion of the trial drug. Stability of brain metastases should be determined prior to the first dose of the trial drug infusion. Patients with asymptomatic brain metastases (i.e., no neurologic symptoms, no need for medication, and no lesion with a longest diameter \\>1.5 cm) may be enrolled, but will be required to undergo periodic imaging;\n2. subjects with grade ≥2 corneal abnormalities present at screening;\n3. adverse effects of prior antineoplastic therapy that have not recovered to a CTCAE 5.0 grade rating of ≤ grade 1 or to the level specified in the entry criteria (except for toxicities judged by the investigator to be of no safety risk, e.g., alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy)\n4. other malignancies within the previous 5 years, usually with the exception of the following: a. any other aggressive malignancy (for which the subject has had adequate treatment) for which disease-free status has persisted for \\>3 years and which, in the investigator's assessment, would not interfere with the assessment of oncologic efficacy; and b. cured basal cell or squamous cell skin cancers, superficial bladder cancers, and locally curable cancers such as prostate, cervical, or breast cancer in situ;\n5. a history of immunodeficiency, including a positive HIV antibody test, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation\n6. interstitial lung disease that is symptomatic or may interfere with pulmonary toxicity monitoring associated with the test drug;\n7. a history of serious cardiovascular or cerebrovascular disease, including, but not limited to: severe cardiac rhythm or conduction block, such as ventricular arrhythmia requiring clinical intervention, degree III atrioventricular block, etc.; QTc intervals \\> 480 ms on 12\u002F15 lead ECG at rest; acute coronary syndrome, congestive heart failure, aortic dissection, stroke within 6 months prior to the first infusion or other grade 3 or higher cardiovascular events; NYHA cardiac function classification ≥ grade II or LVEF \\\u003C50%; clinically uncontrollable hypertension;\n8. any of the following within 4 weeks prior to the first trial drug infusion:\n\n   * Has had major surgery (defined as surgery requiring general anesthesia).\n   * has participated in a clinical trial and received investigational treatment or used an investigational device.\n   * Undergoing or planning other antineoplastic therapy outside of this study protocol (certain specific antineoplastic agents may be excluded from the 4 weeks prior to drug infusion, e.g., oral fluorouracil ≥ 2 weeks; mitomycin C, nitrosoureas ≥ 6 weeks; and small molecule targeted therapy ≥ 2 weeks);\n9. any of the following within 2 weeks prior to the first trial drug infusion:\n\n   * Having had localized palliative radiotherapy.\n   * Received herbal\u002Fproprietary Chinese medicines that are clearly indicated for the treatment of oncological indications.\n   * Has had minor surgery (other than major surgery, but diagnostic procedures such as incision and\u002For needle core biopsy are not considered minor surgery).\n   * Received blood transfusion, erythropoietin, granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor therapy;\n10. known intolerance to anti-EGFR monoclonal antibodies resulting in discontinuation due to rash, gastrointestinal toxicity, or other Grade 3 or 4 toxicity;\n11. Hepatitis B or C virologic testing at screening meets any of the following:\n\n    * HBsAg positive and peripheral blood hepatitis B virus deoxyribonucleic acid (HBV-DNA) titer test ≥1000 copies\u002FmL or ≥200 IU\u002FmL;\n    * Positive antibody to HCV;\n12. known severe allergic reaction to any component of the test drug or multiple drugs;\n13. third interstitial fluid that, in the opinion of the investigator, is clinically uncontrollable;\n14. any other serious or uncontrollable medical condition, active infection currently requiring intravenous anti-infective therapy, abnormal physical examination, abnormal laboratory tests, abnormal mental status, or psychiatric illness that, in the opinion of the Investigator, results in increased risk to the subject or otherwise affects the evaluation of study results.",{"count":168,"type":20},55,[50],"This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.",[25],"2025-09-09",{"date":174,"type":30},"2025-09-11",{"date":176,"type":30},"2025-06-09",{"date":178,"type":20},"2026-05-31",{"name":180,"class":62},"Taizhou Mabtech Pharmaceutical Co.,Ltd",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":48,"phases":190,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":38},"100568653","pet-image-exploration-of-novel-tracer-68ga-fapi-jnu-imaging-studies-in-patients-with-malignant-tumors-100568653","NCT06684028","PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors","Inclusion Criteria:\n\n1. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;\n2. Age 18-85 years old, male or female;\n3. Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;\n4. ECOG score is 0-3 points;\n\nExclusion Criteria:\n\n1. Patients with a history or allergic constitution to any component of the developer, including alcohol;\n2. pregnant or lactating women;\n3. Patients with mental illness or related history;\n4. Patients who cannot or cannot undergo a PET\u002FCT scan;","85 Years",{"count":189,"type":20},30,[191],"NA","To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.",[194,25],"Cancer",[196,197,198,199],"FAP","FAPI","PET","cancer","2025-01-18",{"date":202,"type":30},"2025-01-22",{"date":204,"type":30},"2023-07-12",{"date":206,"type":20},"2025-07-31",{"name":208,"class":37},"Affiliated Hospital of Jiangnan University"]